東京大学 · Engineering
히로카즈 스기야마 교수의 연구실은 생물약제품 제조 공정의 설계 및 최적화를 중심으로, 환경·건강·안전(EHS) 평가를 통합한 다목적 설계 프레임워크를 개발하고 있습니다. 특히 공정 설계의 초기 단계에서 경제성, 환경 영향, 기술적 타당성 등을 종합적으로 평가할 수 있는 시스템적 접근을 통해 지속 가능한 화학공정을 구현하고자 합니다. 또한, 면역세포나 유전자 조절 메커니즘을 규명하는 생물학적 연구를 통해 암 억제 기전을 밝히는 데에도 기여하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Abstract In recent years, many chemical companies have adopted the concept of sustainable development as a core business value. In this context and with focus on early phases, we present a novel design framework that comprises four stages of process modeling and multiobjective evaluation considering monetary and nonmonetary aspects. Each stage is characterized by the available information as a basis for process modeling and assessment. Appropriate modeling approaches, and evaluation indicators f
In this paper, we present activity models of chemical process design integrating environmental, health and safety (EHS) evaluation as a new element with conventional economic and technical considerations on the basis of the design framework, which defines different stages of early process design with appropriate indicators for multiobjective evaluation. The type-zero method of Integrated DEFinition language or IDEF0 is selected as an activity modeling method for the hierarchical and transparent
Nectin-like molecule 4 (Necl-4)/CADM4, a transmembrane cell-cell adhesion molecule with three Ig-like domains, was shown to serve as a tumor suppressor, but its mode of action has not been elucidated. In this study, we showed that Necl-4 interacted in cis with ErbB3 through their extracellular regions, recruited PTPN13 and inhibited the heregulin-induced activation of the ErbB2/ErbB3 signaling. In addition, we extended our previous finding that Necl-4 interacts in cis with integrin α6 β4 through
A five-step method is proposed for determining the design space of mesenchymal stem cell (MSC) cultivation processes incorporating system dynamics and variabilities. The method uses mechanistic models to capture the MSC cultivation dynamics while performing stochastic simulation to consider influences of the variabilities at raw material, cell, process specification, and operation levels. Simulated time-dependent changes in critical quality attributes (CQAs) are used to determine a dynamic and p
This work presents an uncertainty‐conscious methodology for the assessment of process performance—for example, run time—in the manufacturing of biopharmaceutical drug products. The methodology is presented as an activity model using the type 0 integrated definition (IDEF0) functional modeling method, which systematically interconnects information, tools, and activities. In executing the methodology, a hybrid stochastic–deterministic model that can reflect operational uncertainty in the assessmen
